Solid tumor Clinical Trials in Fairfax, VA
As of June 2026, 101 paid clinical trials are recruiting for Solid tumor in Fairfax, Virginia. Recruiting Solid tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Related specialties in Fairfax
Filter results
101 clinical trials for Solid tumor
·Clear filters·↓ Download CSVA Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
DPTX3186 in Wnt Pathway Activated Solid Tumors
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
A Study of DS5361b in Participants With Advanced Solid Tumors
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
A Study of PHN-012 in Patients With Advanced Solid Tumors
Study of GS-5319 in Adults With Solid Tumors
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
The Vanguard Study: Testing a New Way to Screen for Cancer
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
A Study of ZL-1310 in Participants With Selected Solid Tumors
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
A Study of PHST001 in Advanced Solid Tumors
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
A Study of HS-20110 in Participants With Advanced Solid Tumors
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
About research studies in Fairfax
Fairfax has approximately 515 recruiting research studies across a wide range of therapeutic areas. Virginia hosts the University of Virginia Health System, VCU Health, and Inova Health System, running clinical trials across oncology, cardiology, and neuroscience.
Top Research Study Locations in Fairfax
Researchers run research studies in Fairfax, VA at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| NEXT Virginia | Advanced Solid Tumor, Advanced Solid Tumors, Solid Tumor | 71 |
| Inova Schar Cancer Institute | Breast Cancer, Acute Myeloid Leukemia, Metastatic Breast Cancer | 67 |
| Virginia Cancer Specialists | Breast Cancer, Endometrial Cancer, Ovarian Cancer | 64 |
| NEXT Oncology Virginia | Colorectal Cancer, Advanced Solid Tumors, Breast Cancer | 29 |
| NEXT Oncology | Solid Tumor, Breast Cancer, Cancer | 26 |
| Virginia Cancer Specialists, PC | Breast Cancer, Esophageal Adenocarcinoma, Metastatic Breast Cancer | 19 |
| Inova Fair Oaks Hospital | Breast Cancer, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | 15 |
| Re:Cognition Health | Alcohol Use Disorder, Alzheimers Disease, Amyloid | 7 |
| Inova Fairfax Hospital | Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Cardiovascular Diseases | 5 |
| NEXT Oncology - Virginia | Advanced Solid Tumors, Advanced or Metastatic Solid Tumors, CNS Tumor | 5 |
| Inova Schar Cancer | Advanced Or Metastatic Merkel Cell Carcinoma, Colorectal Cancer, EGFR Inhibitor-associated Rash | 5 |
| Lysosomal Rare Disorders Research and Treatment Center | Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis | 4 |
| NEXT Oncology - Virginia Cancer Specialists | Brain Metastases From HER2 and Breast Cancer, Brain Metastases From Solid Tumors, CNS Metastases | 4 |
| O & O Alpan | Cerebroside Lipidosis Syndrome, Fabry Disease, Gaucher Disease | 4 |
| Zai Lab | Sarcomas, Small-cell Lung Cancer, Solid Tumors | 4 |
| Inova Health Care Services | Angina, Calcium Release Deficiency Syndrome, Femoral Neck Fractures | 3 |
| Lysosomal and Rare Disorders Research and Treatment Center, Inc. | Fabry Disease, Pompe Disease | 3 |
| Nephrology Associates of Northern Virginia Inc | Antineutrophil Cytoplasmic Antibody-associated Vasculitis, Atherosclerotic Cardiovascular Disease in Patients With ESKD, Primary IgA Nephropathy | 3 |
| The Retina Group of Washington | DME, Diabetic Macular Edema, Diabetic Macular Edema (DME) | 3 |
| Virginia Cancer Specialists PC | Anaplastic Lymphoma Kinase (ALK) Positive, Extensive Stage Small-cell Lung Cancer, Non-small Cell Lung Cancer (NSCLC) | 3 |
| Exelixis Clinical | Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, Hormone-receptor-positive Breast Cancer | 3 |
| Avenzo Therapeutics Recruiting Site | Biliary Tract Cancer (BTC), Epithelial Tumor, HR+, HER2-, Advanced Breast Cancer | 2 |
| Dren Investigational Site | Aggressive NK Cell Leukemia, Castrate Resistant Prostate Cancer, Cervical Cancer | 2 |
| GSK Investigational Site | Alzheimer's Disease, Multiple Myeloma, Newly Diagnosed Multiple Myeloma | 2 |
| George Mason University | Hiv, Major Depressive Disorder (MDD), Mental Health Issue | 2 |
Active & Upcoming Studies in Fairfax (2026)
Recruiting trials in Fairfax grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (353 active studies)
- A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors · Phase 1 · Cogent Biosciences, Inc.
- Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors · Phase 1 · Regor Pharmaceuticals Inc.
Cardiovascular (7 active studies)
- Palliative Care Intervention to Improve Health Related Quality of Life for Patients on Long-Term LVAD Support · Medstar Health Research Institute
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin · Phase 3 · AstraZeneca
Neurology & pain (5 active studies)
- Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease · Phase 2 · Lighthouse Pharmaceuticals, Inc.
- A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease · Phase 4 · Impax Laboratories, LLC
Mental health & behavior (3 active studies)
- ALTO-207 in Adults With Treatment-resistant Depression (TRD) · Phase 2 · Alto Neuroscience
- A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1) · Phase 2 · Eli Lilly and Company
Eye & vision (3 active studies)
- CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME · Phase 3 · EyePoint Pharmaceuticals, Inc.
- A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy · Astellas Pharma Global Development, Inc.
HIV / STI (1 active study)
- PrEP Intervention in Prince George's County, Maryland · George Mason University
Diabetes & metabolic (1 active study)
Common conditions studied in Fairfax
- Advanced Solid Tumor (33 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Breast Cancer (27 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Ovarian Cancer (26 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Advanced Solid Tumors (25 active studies). Recruiting Advanced Solid Tumors studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Endometrial Cancer (25 active studies). Recruiting Endometrial Cancer studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Colorectal Cancer (21 active studies). Colorectal cancer trials explore novel chemotherapy combinations, targeted agents, and immunotherapy for microsatellite-instability-high tumors.
Leading research sponsors in Fairfax
- AstraZeneca
- AbbVie
- Merck Sharp & Dohme LLC
- Eli Lilly and Company
- Janssen Research & Development, LLC
Local regulations and guidelines
Clinical trials in Virginia are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Virginia research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Fairfax. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Fairfax
Hipa.ai aggregates every recruiting study in Fairfax from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Fairfax?
There are approximately 515 recruiting clinical trials in Fairfax, Virginia listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Fairfax pay participants?
Most recruiting trials in Fairfax compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Fairfax?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Fairfax?
The most common conditions under active study in Fairfax include Advanced Solid Tumor (33), Breast Cancer (27), Ovarian Cancer (26), Advanced Solid Tumors (25), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Fairfax?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Fairfax on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Fairfax?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Fairfax?
Recruiting research sites in Fairfax include NEXT Virginia, Inova Schar Cancer Institute, Virginia Cancer Specialists, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Fairfax right now?
The largest active categories in Fairfax are Cancer & tumors (353), Cardiovascular (7), Neurology & pain (5). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.